Cholesterol reduction in cyclosporine-treated renal transplant patients: effect on platelet-derived growth factor levels and platelet activation.
Rigatto
O
O
Section of Nephrology, University of Manitoba, Winnipeg, Canada.
Rush
D
D
Perry
Y
Y
Walker
S
S
Bose
R
R
Bolli
P
P
D001161:Arteriosclerosis / Q000097:blood / Q000139:chemically induced*; D002784:Cholesterol / Q000097:blood*; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D015539:Platelet Activation / Q000187:drug effects; D010982:Platelet-Derived Growth Factor / Q000378:metabolism*; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D010982:Platelet-Derived Growth Factor; D016572:Cyclosporine; D002784:Cholesterol